Timely confirmation of gastro-esophageal reflux disease via pH monitoring: estimating budget impact on managed care organizations

Curr Med Res Opin. 2008 May;24(5):1317-27. doi: 10.1185/030079908x280680. Epub 2008 Mar 27.

Abstract

Background: Current guidelines recommend the use of pH monitoring to confirm the diagnosis of acid reflux in patients with a normal endoscopy. This analysis evaluated the financial impact of pH monitoring with the wireless pH capsule on a managed care organization (MCO) in the United States.

Methods: A decision model was constructed to project total 1-year costs to manage GERD symptoms with and without the adoption of wireless pH capsules in a hypothetical MCO with 10 000 eligible adult enrollees, of whom 600 presented with GERD-like symptoms. Costs of GERD diagnosis, treatment, and symptom management for those in whom a GERD diagnosis was ruled out by pH monitoring were assessed. The incremental per-member-per-month (PMPM) and per-treated-member-per-month (PTMPM) costs were the primary outcomes. Data sources included literature, expert input, and standardized fee schedules.

Results: An increase of 10 percentage points in the use of pH monitoring with wireless pH capsules yielded incremental PMPM and PTMPM costs of $0.029 and $0.481, respectively. The costs of proton pump inhibitor (PPI) therapy to the plan dropped to $236,363 from $238,086, while increases were observed in pH monitoring (from $16 739 to $21 973) and non-GERD therapy costs (from $1392 to $1740). The results were sensitive to the percentage of patients requiring repeat endoscopy before wireless pH monitoring and the cost of PPIs.

Conclusions: Timely and increased use of pH monitoring as recommended in published guidelines leads to less unnecessary use of PPIs with a modest budgetary impact on health plans.

MeSH terms

  • Adult
  • Aged
  • Budgets
  • Cost of Illness*
  • Cost-Benefit Analysis
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / economics
  • Esophageal pH Monitoring / economics*
  • Esophageal pH Monitoring / instrumentation
  • Esophagoscopy / economics
  • Female
  • Gastroesophageal Reflux / diagnosis*
  • Gastroesophageal Reflux / drug therapy
  • Gastroesophageal Reflux / economics*
  • Humans
  • Male
  • Managed Care Programs / economics
  • Managed Care Programs / organization & administration*
  • Middle Aged
  • Models, Economic
  • Predictive Value of Tests
  • Proton Pump Inhibitors*
  • Proton Pumps / economics
  • Risk Assessment
  • United States

Substances

  • Enzyme Inhibitors
  • Proton Pump Inhibitors
  • Proton Pumps